A new study by Mayo Clinic Researchers calls into question the current standard of care for treating smoldering multiple myeloma.
The cancer drug lenalidomide can delay the symptoms of myeloma, leading to delayed disease progression and preventing organ damage, according to a new study presented at the 2019 American Society of Clinical Oncology Annual Meeting.
The findings call into question the current standard of care for smoldering multiple myeloma (SMM), which is simply observation and no therapy.
"At present, the standard of care for smoldering multiple myeloma is observation without therapy," S. Vincent Rajkumar, MD, a Mayo Clinic hematologist and senior author of the trial, said in a statement. "We found that treatment of smoldering myeloma delays progression to symptomatic myeloma and can prevent damage to organs that occurs in multiple myeloma."
The findings of the study, which is the largest randomized trial of SMM to date, aligns with a smaller 2015 Spanish study involving lenalidomide and dexamethasone. In the 2019 study, 28% of participants experienced serious adverse events. However, investigators said the events were considered manageable.
The study did not make clear if the benefits were the result of one drug or a combination of both.
The study included 182 individuals, with 92 receiving the lenalidomide. The remaining 90 participants were simply observed, as is the current standard clinical practice. Nearly half of the patients taking lenalidomide responded to the treatment. Patients who were not taking the drug showed no change.
"We show that it is possible to delay progression to multiple myeloma, a serious cancer with significant morbidity, by early therapy administered when the disease is still asymptomatic," Rajkumar said.
The findings of the 2019 study, which was conducted by the Eastern Cooperative Oncology Group, in conjunction with the findings of the 2015 Spanish study, suggest a new standard of care for patients with middle- to high- risk smoldering multiple myeloma, according to investigators.
Reference
Lonial S, Jacobus SJ, Weiss M, et al. E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma. Presented at: 2019 American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2019; Chicago, IL. Abstract 8001.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More